Bolt Biotherapeutics Inc
BOLT
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.26M
Close$
Share Statistics
| Market cap | $7.26 Million |
|---|---|
| Enterprise Value | $18.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17.85 |
| Beta | 1.17 |
| Outstanding Shares | 1,869,924 |
Return
| Return on Equity | -149.23% |
|---|---|
| Return on Assets | -61.59% |
| Return on Invested Capital | -76.30% |
Valuation & Multiples
| P/E Ratio | -0.24 |
|---|---|
| PEG | 0.69 |
| Price to Sales | 1.35 |
| Price to Book Ratio | 0.41 |
| Enterprise Value to Revenue | 2.86 |
| Enterprise Value to EBIT | -0.6 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.23 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-2.85
Average shareholder expectationRevenue Estimate
$1.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-2.79
Average shareholder expectationRevenue Estimate
$1.50 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 32.80%▲ 1.40% |
|---|---|
| Total Invested | $2.49M▼ 24.49% |
| Investors Holding | 24▲ 3.00% |
ESG Score
No data
About Bolt Biotherapeutics Inc
65 employeesBolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjug...